|
NICE (UK) releases final guidance for access to Harvoni, Viekirax and Daklinza hepatitis C treatments
(Preview)
Following the release last month of provisional recommendations, the National Institute for Health and Care Excellence (NICE) has now published final guidance recommending Harvoni, Viekirax (with or without Exviera) and Daklinza for treatment of people with certain genotypes of hep C.The NI...
|
Cinnamon Girl
|
0
|
1065
|
|
|
|
|
Gilead applies for FDA approval for sofosbuvir & velpatasvir combination treatment
(Preview)
On September 21, 2015 Gilead submitted their Phase 3 data of a once-daily combination of sofosbuvir (polymerase inhibitor) and velpatasvir (NS5A inhibitor) with and without ribavirin to treat genotype 1 through 6 patients to the FDA for marketing approval.Patients with decompensated cirrhos...
|
Cinnamon Girl
|
0
|
1164
|
|
|
|
|
UK Generic Breakthrough
(Preview)
From the blog of Greg Jeffreys, good news on the importation of generic medication for personal use. I hope this is a signal of equal opportunities for people everywhere. UK Generics Hep C Medication Importation
|
Tig
|
0
|
1101
|
|
|
|
|
FDA Warning Issued over Viekira Pak/Technivie
(Preview)
The FDA just issued a warning regarding a potential risk to patients with cirrhosis (advanced fibrosis) that are taking the Abbvie drug protocols Viekira Pak and Technivie. Abbvie is updating their literature and notifying physicians of this possible adverse reaction. If you fall into this cate...
|
Tig
|
9
|
2446
|
|
|
|
|
NICE (UK) announce criteria for access to Daklinza, Harvoni, Viekirax and Exviera
(Preview)
Very good news for Hep C patients in the UK with Gen 1 and 4, and some with Gen 3!The National Institute of Clinical Excellence (NICE) have announced which of the new treatments would be made available by the NHS to people living with hepatitis C. This NICE decision is concerned with widening access be...
|
Cinnamon Girl
|
0
|
1274
|
|
|
|
|
Gilead Releases Phase 3 SVR Rates-Sovaldi/Velpatasvir (GS-5816)
(Preview)
Some very good news indeed! WOOT!! "FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 21, 2015-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced topline results from four international Phase 3 clinical studies (ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4) evaluating a once-daily, f...
|
Tig
|
5
|
1916
|
|
|
|
|
LOOK - Healio HCV Updates
(Preview)
Here are some new updates that you should find helpful and informative. FDA Updates Labeling for Olysio C Tracker App Caffeine Decreases Fibrosis in HCV Infected Men
|
Tig
|
0
|
1074
|
|
|
|
|
October 2015 - HCV Advocate Newletter
(Preview)
Lots of very interesting reading in this month`s issue, including articles on: Post treatment issues and how long it takes for the drugs to be eliminated from the body; An examination of RAVs and what causes them to occur: Up to date news on the latest drug developments. Link to full newsletter... htt...
|
Cinnamon Girl
|
1
|
984
|
|
|
|
|
FDA grants Priority Review for 3 New Drug Applications for Daklinza
(Preview)
Bristol Myers-Squibb announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review three supplemental New Drug Applications for Daklinza(daclatasvir), an NS5A replication complex inhibitor, for use with sofosbuvir with or without ribavirin.The applic...
|
Cinnamon Girl
|
0
|
987
|
|
|
|
|
The Biotech Sector is Exploding
(Preview)
Here's an interesting article on Biotech stocks, IPO's and Big Pharma's battle to be the best (and wealthiest) industry. "Gilead's Sovaldi and Harvoni were breakthrough treatments for the disease, but they were also the poster children of overpriced drugs. At list prices, a regimen o...
|
Tig
|
7
|
1757
|
|
|
|
|
New HCV ICD-10 Diagnosis Coding Update
(Preview)
An update effective Oct. 01, 2015 was made to the U.S. Medical diagnosis coding system. It's known as the ICD-10 or the International Classification of Diseases, 10th Revision. These are the codes your doctor must use when submitting your records to insurance for reimbursement. If these codes are...
|
Tig
|
0
|
1093
|
|
|
|
|
An Australian hepatitis C sufferer has taken on Gilead by importing Sovaldi from India
(Preview)
http://www.abc.net.au/news/2015-08-20/hepatitis-c-sufferer-imports-life-saving-drugs-from-india/6712990
|
Matt Chris
|
5
|
1362
|
|
|
|
|
Sofosbuvir- India
(Preview)
Hello All, I am in process of getting my hands on Sofosbuvir tabs in India for around 350 USD per bottle. I will ke you guys posted. I have seen some websites selling it for 600-650 USD I don't know real or fake but still pricey. If anyone really needs it get I can arrange it in less that 500 or may be 450 USD o...
|
vaibhav86
|
3
|
1605
|
|
|
|
|
Living Well with HCV
(Preview)
I found an interesting resource that I wanted to share. There are several short slideshows presented on a variety of Hep C topics. It's interesting and educational. I think it can help inform those new to the disease, as well as the familiar veterans. It may be a resource you can use to help educate frie...
|
Tig
|
0
|
919
|
|
|
|
|
Hep C Treatment: A Sudden and Unexpected Development
(Preview)
Looks like the stupidity and greed is going global [smh] "A sudden and unexpected development has occurred that reminds us that the reach of Big Pharma into governments and bureaucracies is profound. Because of its money and influence we have just seen how Big Pharma is threatening to postpon...
|
Tig
|
3
|
1654
|
|
|
|
|
Ongoing real world study reports high SVR rates for VIEKIRAX + EXVIERA in Gen 1
(Preview)
New real world interim data from the independent AMBER study were presented for AbbVie's VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) with or without ribavirin in gen 1 chronic hep C infected patients. The primary endpoint of the study is the percentag...
|
Cinnamon Girl
|
0
|
1016
|
|
|
|
|
Daklinza GT 3 Approval Update in the EU
(Preview)
Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission Daklinza in combination with sofosbuvir is the first 12-week all-oral therapy for genotype 3 patients without cirrhosis in Eur...
|
Tig
|
1
|
934
|
|
|
|
|
Used Drug Disposal
(Preview)
We have often been asked what we can or should do with left over or expired medication. Here is a website that discusses your options. http://www.disposemymeds.org/
|
Tig
|
0
|
880
|
|
|
|
|
September 2015 - HCV Advocate Newletter
(Preview)
This months (new look) newsletter from the HCV Advocate website contains some interesting and very informative articles including `Hep C in Children`, and `Big Questions About Hep C - answers to some commonly asked questions about HCV and treatment`. Pdf link... http://hcvadvocate.org/news/...
|
Cinnamon Girl
|
0
|
1034
|
|
|
|
|
One in Four Denied Initial TX Approval -Study
(Preview)
Yale Medicine ran a small study last year investigating the approval process for the Harvoni protocol. I personally think in the time following this report, we saw an increase in this percentage. We knew we weren't imagining it... Let's hope for a rapid improvement in these numbers. It's good to kno...
|
Tig
|
1
|
945
|
|
|
|
|
interesting new tx
(Preview)
development-program-at-the-international-liver-congress-2015-300062654.html
|
drummerman
|
0
|
894
|
|
|
|
|
Forgotten History:The Hunt for Undiagnosed Patients with HCV
(Preview)
A long article on the history of and effort to get people in for testing and treatment. I found the article to be very telling of many of the situations we all found ourselves in at one time or another. The behavior, the stigma and the fight to get treated. I think you'll find this interesting. Healio is a g...
|
Tig
|
0
|
768
|
|
|
|
|
FDA Grants Breakthrough Designations to Merck’s Hepatitis C Candidate
(Preview)
After rescinding breakthrough designation earlier this year, the FDA re-established two new designations for an oral combination tablet of grazoprevir/elbasvir for the treatment of chronic hepatitis C virus infection genotype 4 and genotype 1 with end stage renal disease on hemodialysis, ac...
|
Matt Chris
|
1
|
1370
|
|
|
|
|
Cipla announces the launch of generic drug Sofosbuvir in India, `Hepcvir`
(Preview)
India, Mumbai. March 25th, 2015 -Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, Cipla is now all set to make the drug Sofosbuvir available to Indian patients in a week`s time.Full pres...
|
Cinnamon Girl
|
5
|
2770
|
|
|
|
|
Hepatitis C Competitive Landscape: The Holy Grail
(Preview)
An interesting op-ed with some current trends and results as researched by the author. The graphics and spreadsheet are quite informative.The Holy Grail
|
Tig
|
1
|
856
|
|
|
|
|
FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Gen. 3
(Preview)
Bristol-Myers Squibb Company announced today (24 July, 2015) that Daklinza (daclatasvir), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). This approval marks the first time patients with chronic hepatitis C virus (HCV) genotype 3 have...
|
Cinnamon Girl
|
3
|
1017
|
|
|
|
|
FDA approves `Technivie` for treatment of patients with Gen. 4
(Preview)
The U.S. Food and Drug Administration today (24th July, 2015) approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis)...
|
Cinnamon Girl
|
2
|
1217
|
|
|
|
|
July Newsletter HCV Advocate
(Preview)
FYI. Some more stuff about herbs. http://hcvadvocate.org/news/NewsUpdates_pdf/Advocate_2015/advocate0715.pdf
|
mallani
|
0
|
838
|
|
|
|
|
At least 7 states limit patient costs for high-priced drugs
(Preview)
http://www.pbs.org/newshour/rundown/least-7-states-limit-patient-costs-high-priced-drugs/
|
RudiRoo
|
2
|
1088
|
|
|
|
|
Abbvie announces 100% SVR12 response in Turquoise-111 Phase 3b study results
(Preview)
NORTH CHICAGO, Ill., June 24,2015AbbVie today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b chronic hepatitis C virus infected adult patients with compensated liver cirrhosis. Pa...
|
Cinnamon Girl
|
1
|
1033
|
|
|
